Showing results (11-20 of 61) with videos related to
Sort By:
Pageof 7
Research Involvement and Engagement|June 19, 2024
Patient and public involvement and engagement in the development of innovative patient-centric early phase dose-finding trial designsEmily Alger, Mary Van Zyl, Olalekan Lee Aiyegbusi, et al.Clinical Lung Cancer|February 13, 2026
Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in EnglandFabio Gomes, Niall Gilding, Vivian Tan, et al.Plos One|July 7, 2022
Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapyFrancesca Castagnoli, Simon Doran, Jason Lunn, et al.Cancers|March 14, 2026
Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung CancerPedro Cruz, Cristina Boixareu, Diogo J Silva, et al.The Oncologist|June 28, 2022
Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer ForumJulia Lai-Kwon, Alyssa M Vanderbeek, Anna Minchom, et al.Sarcoma|May 29, 2010
Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcomaAnna Minchom, Robin L Jones, Cyril Fisher, et al.Lung Cancer (Amsterdam, Netherlands)|May 9, 2021
Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyondKroopa Joshi, Abdul Muhith, Mariam Obeid, et al.Journal of Hematology & Oncology|July 3, 2025
Treatment-related adverse events of antibody drug-conjugates in clinical trialsHarold Nathan Tan, Marta Ascanio Morcillo, Juanita Lopez, et al.Plos One|November 26, 2019
A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesotheliomaAnna Minchom, Daisy Mak, Ranga Gunapala, et al.Cancer Treatment and Research Communications|December 14, 2020
Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experienceWanyuan Cui, Nadia Yousaf, Jaishree Bhosle, et al.Pageof 7